Table 3.
Methodological quality assessment of the included trials.
| Author | Year | Allocation generation | Allocation concealment | Double blinding | Duration of follow-up* | Loss to follow-up (%) | Data analysis | Other bias |
|---|---|---|---|---|---|---|---|---|
| Rovetta and Monteforte [21] | 1998 | Unclear | Unclear | Unclear | 6 months | 0 | ITT | |
|
| ||||||||
| Calis et al. [12] | 2006 | Unclear | Unclear | Blinded assessor | 3 months | 0 | ITT | |
|
| ||||||||
| Hsieh et al. [13] | 2012 | Computer-generated random numbers | Unclear | Blinded assessor | 3 months | 10 | PP | |
|
| ||||||||
| Park et al. [22] | 2013 | Computer-generated random numbers | Adequate | Blinded participants and assessor | 10 weeks | 10 | PP | Different volumes of lidocaine administered |
*After first evaluation.
ITT: intention-to-treat; PP: per protocol.